Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.

PURPOSE: In two dose-ranging crossover studies, the long-acting muscarinic antagonist umeclidinium (UMEC) was assessed as monotherapy in patients with asthma not treated with inhaled corticosteroids (ICS) (NCT01641692 [study 1]) and combined with the ICS fluticasone furoate (FF) in patients with asthma symptomatic on ICS (NCT01573624 [study 2]). The present study aimed to further characterise the UMEC dose-response relationship with change from baseline trough forced expiratory volume in one second (FEV1) (day 15).
METHODS: A model-based approach using non-linear mixed-effects analyses was used to assess data from studies 1 and 2.
RESULTS: Within the Study 1 dose range, no significant dose-response was demonstrated. In study 2, the slope-intercept on log-dose model showed a mild dose-response, with a 10 % probability of a 0.075-L FEV1 improvement with FF/UMEC 100/250 mcg; period 1 data (with an absent carryover effect) indicated an 88 % probability of a 0.075-L FEV1 improvement.
CONCLUSION: The model-based approach in study 2 identified FF/UMEC doses warranting further investigation.

RCT Entities:   Population Interventions Outcomes